Kornimate/medical-research-clean huggingface dataset:
biomarkers in retinitis pigmentosa

Conditions: Retinitis Pigmentosa

Summary: the objective of this study is to discover biomarkers that demonstrate a correlation between the severity of retinitis pigmentosa (rp) and the thickness of the retinal pigment epithelium (rpe). these biomarkers will serve as prognostic indicators for various kinds of retinitis pigmentosa. the objective of this study is to find biomarkers that establish a correlation between the severity of retinitis pigmentosa and the thickness of the retinal pigment epithelium (rpe), which can serve as a prognostic indicator for retinitis pigmentosa.

after a genetic confirmation of rp and classification, the patients will undergo a comprehensive ophthalmological examination that includes the following tests: slit-lamp anterior segment, visual acuity direct and indirect ophthalmoscopy, intraocular pressure, and family history.in order to evaluate the potential role of rpe in the advancement of rp, hd-oct and oct angiography images of the outer retina using oct devices will be performed. analysis of high-resolution images captured with an ultrawidefield system using a zeiss clarus device in order to determine the condition of the peripheral retina.finally, flicker electroretinogram (ferg) performed on the central retina (macula), to assess the central macular function within an 18° field of view. this assessment involved measuring the response of the macula to a flickering stimulus with a frequency of 41 hz, which is commonly done in routine clinical practice.

Eligibility criteria:
inclusion criteria: * patients who are able to read and sign informed consent * patients with retinitis pigmentosa confirmed by genetic test. * patients older than or equal to 18 years of age exclusion criteria: * other retinal diseases such as macular hole, retinal detachment, macular neovascularization. * corneal surgery in the last 12 months * glaucoma with pressure above 25 mmhg in the last three months. * best correct visual acuity below 1/10 in at least one eye.

Keywords: retinitis pigmentosa retinal degeneration multimodal imaging electroretinography retinal pigment epithelium and outer retinal atrophy (rora)
combating physical inactivity pandemic in kindergartens

Conditions: Physical Activity; Cardiorespiratory Fitness

Summary: the aim of this study is to examine the effects of a kindergarten-based, parent-involved intervention during the upper kindergarten year (k3) on physical activity and physical fitness in preschool children.

this study is a two-arm cluster randomized controlled trial. kindergartens will be randomly allocated to two groups: the usual care group and the intervention group. the usual care group will continue with their usual curriculum, which includes 30 minutes of daily physical activity stipulated by the hong kong sar government's education bureau. the intervention group will receive an additional 2.5 hours of physical activity per week in addition to the stipulated 30 minutes of daily physical activity. outcome measures will be examined at baseline, 10 months (post-intervention), and 16 months (follow-up).

Eligibility criteria:
inclusion criteria 1. children aged 5-6 years (limited number of children may be between 4-5 and 6-7 years) 2. able to communicate in chinese 3. able to participate in physical activity in a standard kindergarten setting exclusion criteria: 1. inherent or serious disease limiting participation in physical activity (e.g., congenital heart disease, pediatric cancer, down syndrome). 2. diagnosed mental illness impairing daily behavior and performance (e.g., anxiety disorder, depression, attention deficit hyperactivity disorder, psychotic disorders, autism spectrum disorder). 3. physical disability (e.g., physical handicap, assistive device to walk). 4. visual or hearing impairment. 5. cognitive deficit or intellectual disability that requires special care and educational needs (e.g., handicapped children with learning difficulties).

Keywords: childhood physical inactivity childhood obesity
3d modeling to improve hip arthroscopy outcomes

Conditions: Femoroacetabular Impingement

Summary: this study will pilot the use of 3d printed models of the hip, for use in pre-operative planning and patient communication to improve clinical outcomes and patient engagement. this method will be implemented in the setting of femoroacetabular impingement (fai), with the goal of identifying and measuring specific anatomical pathologies and impingement (range of motion) risks, to communicate a pre-operative plan to both the surgical team, and the patient.

following a standard of care pre-operative ct scan, a 3d rendering of the ct scan will be completed. the de-identified ct scan data will be transferred to the clemson university bioengineering department, and a 3d modeling software will convert it to a computer model that will then be 3d printed. during the doctor-patient pre-operative consultation, the 3d printed model will be used to assist the doctor in describing the patient's pathology and upcoming surgical procedure. in this pilot study, the surgeon will make measurements and estimates of resection for the femoroplasty and acetabuloplasty off of 2d ct scan, mri, and x-rays. this will then be compared quantitatively to the results of the 3d model/3d printing measurements. surgeon debriefings will occur postoperatively to determine the benefit of the model and how well it matched up to what the surgeon experienced during the surgery. fai involves complex anatomic morphology which can be unique to each patient. a thorough understanding of the type and specifically location of impingement is paramount to successful results if surgery is required. 2d imaging has limitations when analyzing a 3d anatomic lesion. 3d printed hip models have the potential to provide superior preoperative planning and subsequent surgical results. in addition, 3d models can potentially improve patient understanding, expectations, and outcomes.

Eligibility criteria:
inclusion criteria: * surgical candidate for a hip arthroscopy for the treatment of femoroacetabular impingement * subject is willing to sign the informed consent. * subject is at least 18 years of age. exclusion criteria (n/a)
persistent atrial fibrillation without the evidence of low-voltage areas

Conditions: Persistent Atrial Fibrillation; Catheter Ablation; Low Voltage Areas

Summary: an effective therapy of persistent atrial fibrillation beyond pulmonary vein isolation remains unsatisfactory. targeting endocardial low-voltage areas represents an approach of substrate modification. this prospective, randomized study investigated the efficacy of ablation of low-voltage areas versus pvi and additional linear ablations in patients with persistent atrial fibrillation in terms of single-procedure arrhythmia-free outcome and safety.

pulmonary vein isolation has become the cornerstone of the interventional treatment of paroxysmal atrial fibrillation. for the treatment of persistent atrial fibrillation the data remains unclear. all different approaches remain unsatisfactory for the treatment of persistent atrial fibrillation, including single pulmonary vein isolation, targeting endocardial areas of low-voltage, identifying areas with complex fractionated atrial electrograms (cfae), ablating linear lines such as an anterior line, a roof-line or mitral isthmus line. recurrence rates are still higher as compared to paroxysmal atrial fibrillation ablation. several studies showed a good correlation between the volume of low-voltage areas (lva) and the burden of atrial fibrillation. earlier studies that investigated ablation therapy using a substrate-guided ablation as compared to circumferential pulmonary vein isolation (cpvi) alone, mostly showed no significant difference in recurrence rates between both approaches. in contrast, some other studies showed better outcomes when targeting low-voltage areas. however, there was significant heterogeneity in patient selection, mapping and ablation strategies and therefore, comparisons are hard to make. the patients are randomized into three different treatment arms (group 1: pvi alone if no low voltage areas are detected, group 2: pvi alone if low voltage areas are detected, group 3: pvi plus ablation of low voltage areas.

Eligibility criteria:
inclusion criteria: * persistent atrial fibrillation according to the current guidelines * age \> 18 years * patient information exclusion criteria: * minors
anxiety, pain et analgesia nociception index (ani) in palliative care

Conditions: Pain; Anxiety; Palliative Care

Summary: the main objective of this study is to evaluate the correlation between ani and pain scores and the correlation of ani and anxiety scores in communicative patients in palliative care. the chosen event with a risk of pain and/or anxiety is the first bed bath after admission. the secondary objectives aim to identify ani score thresholds which would be predictive of pain and/or anxiety and to figure out some individual factors influencing ani scores.

pain and anxiety assessments are still challenges for palliative care teams. anxiolytics and painkillers are the usual tools but sometimes the symptoms and so the drugs to deliver are difficult to distinguish. for patients with maintained communication abilities, pain self-assessment using visual analogic scores are the gold standard. could pain assessment be optimised thanks to ani? ani is used in anaesthesiology and intensive care. the ani system is based on the analysis of intra-cardiac variability. based as an electrocardiograph with two electrodes on the patient's chest, it measures the balance between sympathetic/parasympathetic tones leading to a pain score. this score is predictive of pain occurrence, leading to an early analgesic treatment and a better control of pain with less quantity of drugs. however, some studies reported that anxiety and emotions could influence ani pain score. to test this hypothesis in palliative care field, this study compares pain and anxiety vas to ani scores before, during and after the bed bath.

Eligibility criteria:
inclusion criteria: * admitted in palliative care -≥18 years old * enough communication abilities to use vas * non opposition of the patient non-inclusion criteria : * previous bed bath already provided to the patient in the palliative unit (anxiolytic and analgesic strategies already adapted limiting the risk of pain or anxiety and the power of the study ) * adult under legal protection (guardianship, trusteeship ...) * contraindication of ani : respiratory rate \< 10/min, non sinusal cardiac rythm, cardiotropic treatments * behavioural disorders : agitation, confusion (richmond scale score \> ou = 1) * alertness disorders : somnolence (richmond scale score \< ou = -1) * no french speaking exclusion criteria: * providing the bad bath is impossible * secondary opposition of the patient

Keywords: pain anxiety communicative palliative care
effect of injectable platelet-rich fibrin (i-prf) in initial treatment of chronic periodontitis

Conditions: Periodontitis

Summary: current treatments of periodontitis have limited efficacy since they fail to suppress microorganisms satisfactorily over time. the aim of present study was to investigate whether there are differences between initial treatment of chronic periodontitis (srp) and srp in conjunction with injectable platelet-rich fibrin (i-prf) application.

current treatments of periodontitis have limited efficacy since they fail to suppress microorganisms satisfactorily over time. the aim of present study was to investigate whether there are differences between initial treatment of chronic periodontitis (srp) and srp in conjunction with injectable platelet-rich fibrin (i-prf) application. thirty patients with chronic periodontitis who had at least two sites with perriodontal pocket depth (ppd) ≥ 4 mm on contralateral side will be involved in the study. using a split-mouth design, patients will be treated with srp + i-prf -(test group) or srp only-(control group). gingival crevicular fluid (gcf) and subgingival plaque will be collected with paper points (dentsplymaillefer, tulsa, oklahoma, usa) at baseline and 1, 3 and 6 months after the treatment. the presence and concentrations of aggregatibacter actinomycetemcomitans (aa), porphyromonas gingivalis (pg), prevotella intermedia (pi) and tannerella forsythia(tf) will be analyzed by real-time polymerase chain reaction (qpcr). periodontal parameters, including bleeding on probing (bop), probing pocket depth (ppd) and the clinical attachment level (cal), will be recorded on both sides, as well as concentration of tnf-alpha (tumor necrosis factor alpha), alp(alkaline phosphatase) and mmp-8 (matrix-metalloproteinase-8).

Eligibility criteria:
inclusion criteria: * a minimum of 6 teeth per quadrant; * a minimum of 2 teeth in each quadrant with a probing depth (pd) ≥5 mm; * bleeding on probing (bop) had to be at ≥40% tooth sites; * no involvement of furcation; * good general health. exclusion criteria: * periodontal therapy within last 12 months; * having surgical therapy; * use of antibiotics over the last 6 months; * ongoing drug therapy that might have an impact on the clinical signs and symptoms of periodontitis; * pregnancy or nursing; * current and former smokers.

Keywords: periodontitis therapy platelet rich fibrin nonsurgical
role of antioxidants in unexplained oligohydramnios,a randomized trial

Conditions: Oilgohydramnios

Summary: to predict the effect of antioxidants in cases of oligohydramnios

type of study: this is a prospective randomized controlled study that was done in department of obstetrics and gynecology of assiut university hospital. aim of the work: 1. to study the effect of antioxidants in cases of oligohydramnios. 2. to study the effect of antioxidants on mode of delivery and neonatal outcome. 3. to commence special recommendations from the study about the use of antioxidants in cases of oligohydramnios of unknown cause and cases of oligohydramnios associated with pregnancy induced hypertension. inclusion criteria: patients with gestational age between 30-34 weeks with: * oligohydramnios of unknown cause. * oligohydramnios assosiatd with pregnancy induced hypertension (pih). exclusion criteria: 1. premature rupture of membranes. 2. oligohydramnios in postdates pregnancy (\>41 weeks). 3. fetal anomalies. 4. iugr. 5. patients using non steroidal anti-inflammatory drugs. assessment of the patients: the target population was assessed to find the participating women suitable for the study, this assessment was done to verify inclusion criteria and to exclude any women has any of the exclusion criteria. ultrasongraphic evaluation: ultrasongraphy was done for estimation of amniotic fluid index by measuring the vertical diameter of the pockets of amniotic fluid in four sections of the uterus and add them together. this gives them a number known as amniotic fluid index (afi). if the afi is less than 5 centimeters, the pregnant woman has oligohydramnios composition of omega-3 plus: soft gelatineous capsule (sedico medical company) each capsule contains: * fish oil (30) % (eicosapentaenoic acid (epa) 18 % / docosahexaenoic acid (dha) 12 % ) natural source of omega 3 fatty acids. * wheat germ oil (tocopherol: n.n.t. 0.22 %) which is rich and natural source of vitamin e (protects the oils from oxidation. besides its well known that requirements of vitamin e increases with increased dietary amounts of polyunsaturated fatty acids).

Eligibility criteria:
inclusion criteria: * patients with gestational age between 30-34 weeks with: * oligohydramnios of unknown cause. exclusion criteria: * 1- premature rupture of membranes. 2- oligohydramnios in postdates pregnancy (\>41 weeks). 3- fetal anomalies. 4- iugr. 5- patients using non steroidal anti-inflammatory drugs. 6 - oligohydramnios assosiatd with pregnancy induced hypertension (pih).

Keywords: oligohydramnios,antioxidant,oxidative stress and pregnancy outcomes
delp for acute hemorrhagic stroke

Conditions: Cerebral Hemorrhage

Summary: delipid extracorporeal lipoprotein filter from plasma (delp) has been found to improve neurological function and life ability of ais patients and approved for the treatment of ais by china food and drug administration (cfda). our recent study imply that the neuroprotective effect of delp involved multiple neuroprotective mechanism such as anti-inflammation, free radical scavenging, and decreasing mmp-9. based on the multiple mechanisms, we argue that delp may exert neuroprotective effect on acute cerebral hemorrhage.


Eligibility criteria:
inclusion criteria: * age: 18-80; * spontaneous cerebral hemorrhage; * deep supratentorial intracerebral hemorrhage (basal ganglia and thalamus) with hematoma volume 5-40ml; * nihss: 4-22; * time from onset to delp is less than 48 hours; * premorbid mrs 0 or 1; * signed informed consent; exclusion criteria: * secondary cerebral hemorrhage (secondary to trauma, tumor, vascular malformation, hemorrhage transformation of ischemic stroke, etc.); * comatose patients on admission (gcs score 3-8 on the glasgow coma scale); * patients with intracerebral hemorrhage ruptured into the ventricle; * planed surgery; * severe hepatic or renal dysfunction, increase in alt or ast (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis; * severe hypertension (systolic blood pressure over 200mmhg or diastolic blood pressure over 110 mmhg); * previous allergy to heparin or calcium; * hypoproteinemia; * unsuitable for this clinical studies assessed by researcher.
tacrolimus blood concentration and transplant-related outcomes in pediatric hsct recipients

Conditions: Graft Vs Host Disease; Transplant Failure; Stem Cell Transplant Complications

Summary: the goal of this retrospective observational study is to investigate any possible association among tacrolimus (tac) blood concentrations, clinical efficacy and tolerability. therefore, the main questions it aims to answer are: 1. to clarify which variables, how and to what extent influence daily tac blood concentrations in pediatric allo-hematopoietic stem cell transplantation (hsct) recipients; 2. to investigate the incidence of graft-versus-host disease (gvhd) and graft failure according to tac exposure. pediatric patients administered tac to prevent gvhd after an allogeneic bone marrow transplantation.

patients undergoing allo-hsct will be recruited at ircc burlo garofolo, collecting demographic and clinical characteristics from electronic medical records in a retrospective manner: age, sex, primary disease, donor type and stem cell source, body weight (bw), white blood cell (wbc) count, platelet count, red blood cell (rbc) counts, hemoglobin (hgb) and hematocrit (hct) levels, red cell concentrate (rcc) transfusions. other clinical laboratory data (i.e., liver and kidney function) will be included, as well as concomitant drugs administered to patients after allo-hsct (i.e, mycophenolate mofetil, steroids, pantoprazole, voriconazole, methotrexate). data will be collected, validated, and presented according to good clinical practice (gcp) principles to support the statistical analyses and subsequent reporting. once selected according to predefined inclusion requirements, data will be collected anonymously; an identification code will be assigned to each case. as per gcp, all collected information will be recorded, handled, and stored in a way that allows its accurate reporting, interpretation, and verification with user access restriction, and data will be retrievable by designated personnel only. because of the retrospective nature of the present research protocol, all eligible patients will be included in the study population only if their medical and laboratory records will be complete. statistical analyses (for descriptive and comparative aims) will be performed stratifying patients by body weight, age, gender, and source of stem cells. univariate and multivariate tests will be used, together with kaplan-meyer tes, cox proportional hazard model and roc curve analysis.

Eligibility criteria:
inclusion criteria: * age of the patients between 0 and 18 years (pediatric) * patients undergoing allogeneic bone marrow transplantation * patients' gvhd prophylaxis with tacrolimus * signed informed consent exclusion criteria: * patients undergoing autologous bone marrow transplantation * patients not undergoing gvhd prophylaxis * patients undergoing cyclosporin prophylaxis * incomplete pharmacokinetic/pharmacodynamic data * lack of any informed consent

Keywords: hsct tacrolimus gvhd pediatric patients
stroke and cerebrovascular diseases registry

Conditions: Stroke; Acute Stroke; Acute Brain Injury; Ischemic Stroke; Hemorrhagic Stroke; Transient Ischemic Attack; Subarachnoid Hemorrhage; Cerebral Ischemia; Cerebral Infarction; Cerebral Stroke; Venous Sinus Thrombosis, Cranial

Summary: this is a single institutional registry database for the patients with stroke and cerebrovascular diseases. stroke is the fifth leading cause of death in the united states. despite extensive research, most of the patients die or suffer from varying degree of post-stroke disabilities due to neurologic deficits. this registry aims to understand the disease and examine the disease dynamics in the local community.

stroke is the fifth cause of all-cause mortality in us http://www.cdc.gov/stroke/facts.htm early identification and treatment not only prevent mortality but also morbidity. recent advancement in the imaging and diagnostic technique and novel therapeutic modalities has dramatically helped to downgrade stroke from the list of top mortality index in the last 3 years. however, studies determining factors which help predict stroke outcome are still underway and much work needs to be done in this direction. many factors currently are used to predict stroke outcome with varying results, for e.g. nihss is a good predictor of stroke outcome at 3 months; however, the investigators need better predictors, outcome scales or outcome measures which are easy, reliable and has better specificity and sensitivity. acute brain injury, transient ischemic attack is a special category of a neurological condition wherein there is an impending devastating outcome if workup is not completed in a timely fashion. there is an urgent need to do investigations with high-risk patients to prevent stroke and further mortality and morbidity. the abcd2 score can help us to risk stratify the tia and to predict the chances of stroke in this specific cohort. however, investigators need better identifiers than already present, to improve the patient changes in secondary prophylaxis of stroke prevention http://www.stroke.org/sites/default/files/resources/tia-abcd2-tool.pdf?docid there is also some correlation of clinical and biochemical predictors in subarachnoid, cerebral venous thrombosis including hunt and hess, sah score, wfns-sah grading among others with variable predictive quality. (rosen et al; neurocritical care; april 2005, volume 2, issue 2, pp 110-118: subarachnoid hemorrhage grading scales).

Eligibility criteria:
inclusion criteria: 1. all patients with a diagnosis of acute brain injury, transient ischemic attack, acute and chronic ischemic and hemorrhagic stroke, subarachnoid hemorrhage, and cerebral venous thrombosis seen in unmh. 2. age \>1 years of age. exclusion criteria: 1. patients who don't have the diagnosis of acute brain injury, transient ischemic attack, acute and chronic ischemic and hemorrhagic stroke, subarachnoid hemorrhage, and cerebral venous thrombosis. 2. patients who have epidural hematoma, subdural hematoma.

Keywords: identification diagnosis management investigation prevalence incidence quality of care hospitalization morbidity disability